Fetal exposure to canakinumab: a report of three pregnancies

Clin Rheumatol. 2022 Apr;41(4):1261-1263. doi: 10.1007/s10067-022-06060-y. Epub 2022 Jan 12.

Authors

Ufuk İlgen¹, Şahin Eyüpoğlu², Müçteba Enes Yayla³, Orhan Küçükşahin⁴

Affiliations

¹ Department of Rheumatology, Trakya University Medical School, 22100, Edirne, Turkey. ufukilgen@gmail.com.
² Department of Nephrology, Ankara University Medical School, Ankara, Turkey.
³ Department of Rheumatology, Ankara University Medical School, Ankara, Turkey.
⁴ Department of Rheumatology, Ankara Yıldırım Beyazıt University Medical School, Ankara, Turkey.

PMID: 35018583
DOI: 10.1007/s10067-022-06060-y

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal* / adverse effects
Antibodies, Monoclonal, Humanized* / adverse effects
Double-Blind Method
Female
Humans
Interleukin-1beta
Pregnancy
Treatment Outcome

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Interleukin-1beta
canakinumab